TrialCancer gene therapy2003

A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.

Suzane Trudel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.